PTGES and osteosarcoma: In addition, the IC50 values for lobaplatin were 15.68 μg/mL (shRNA‐V), 14.59 μg/mL (PTGES sh#1), and 13.72 μg/mL (PTGES sh#2) for MG63 cells and 15.56 μg/mL (shRNA‐V), 14.89 μg/mL (PTGES sh#1), and 14.99 μg/mL (PTGES sh#2) for SOSP‐9607 cells (Figure 6D), which indicates that PTGES knockdown enhances the sensitivity of osteosarcoma cells to lobaplatin in vitro.